Methods and compositions for modulation of blood-neural barrier
Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-α antagonist.
1. A method for treating stroke in an animal in need of such treatment comprising administering to said animal an effective amount of an anti-platelet derived growth factor receptor-α antibody.
2. The method of claim 1 wherein the animal is a mammal.
3. The method of claim 1 wherein the animal is a human.
4. The method of claim 1 wherein the antibody is a monoclonal antibody.
5. The method of claim 1 wherein the antibody is a chimeric, humanized, or fully human antibody.
6. The method of claim 1 wherein the antibody is administered intravenously.
7. The method of claim 1 wherein the antibody is administered by injection.
8. The method of claim 1 wherein the stroke is ischemic stroke.
9. A method for treating stroke in an animal in need of such treatment comprising administering to said animal an effective amount of an an anti-platelet derived growth factor receptor-α in combination with an effective amount of a thrombolytic agent.
10. The method of claim 9 wherein the animal is a mammal.
11. The method of claim 9 wherein the animal is a human.
12. The method of claim 9 wherein the antibody is a monoclonal antibody.
13. The method of claim 9 wherein the antibody is a chimeric, humanized, or fully human antibody.
14. The method of claim 9 wherein the antibody is administered intravenously.
15. The method of claim 9 wherein the antibody is administered by injection.
16. The method of claim 9 wherein the thrombolytic agent is tissue plasminogen activator (tPA).
17. The method of claim 9 wherein the thrombolytic agent is desmoteplase (DSPA).
18. The method of claim 9 wherein the antibody and the thrombolytic agent are administered concurrently.
19. The method of claim 9 wherein the antibody and the thrombolytic agent are administered sequentially.
20. The method of claim 19 wherein the antibody is administered before the thrombolytic agent.
21. The method of claim 19 wherein the antibody is administered after the thrombolytic agent.
22. The method of claim 9 wherein the stroke is ischemic stroke.